A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Clinical trial NCT01085422 · COMPLETED

Trial details

NCT number: NCT01085422
Sponsor: AbbVie (prior sponsor, Abbott)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Prostate Cancer

Start date: 2010-04-01
Primary completion: 2011-06-01
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.